MedPath

BIOHAVEN THERAPEUTICS LTD

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

18

Active:2
Completed:3

Trial Phases

3 Phases

Phase 1:5
Phase 2:8
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials

Phase 2
8 (47.1%)
Phase 1
5 (29.4%)
phase_2_3
3 (17.6%)
Not Applicable
1 (5.9%)

Study of BHV-1400 in IgA Nephropathy

Not Applicable
Not yet recruiting
Conditions
IgA Nephropathy
Interventions
First Posted Date
2025-07-08
Last Posted Date
2025-07-08
Lead Sponsor
Biohaven Therapeutics Ltd.
Target Recruit Count
10
Registration Number
NCT07054684

Study of BHV-1300 in Graves' Disease

Phase 1
Recruiting
Conditions
Graves Disease
Interventions
First Posted Date
2025-05-20
Last Posted Date
2025-05-28
Lead Sponsor
Biohaven Therapeutics Ltd.
Target Recruit Count
15
Registration Number
NCT06980649
Locations
🇦🇺

Site-001, Kotara, Australia

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Phase 2
Recruiting
Conditions
Parkinson Disease
Interventions
Drug: Placebo
First Posted Date
2025-05-16
Last Posted Date
2025-07-02
Lead Sponsor
Biohaven Therapeutics Ltd.
Target Recruit Count
550
Registration Number
NCT06976268
Locations
🇺🇸

Site-028, New Haven, Connecticut, United States

🇺🇸

Site-017, Boca Raton, Florida, United States

🇺🇸

Site-015, Farmington Hills, Michigan, United States

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Solid Tumor
Interventions
First Posted Date
2025-03-13
Last Posted Date
2025-06-08
Lead Sponsor
Biohaven Therapeutics Ltd.
Target Recruit Count
95
Registration Number
NCT06874335
Locations
🇺🇸

Site-106, West Valley City, Utah, United States

🇺🇸

Site-103, Austin, Texas, United States

🇺🇸

Site-101, Irving, Texas, United States

and more 2 locations

Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

Phase 2
Completed
Conditions
Migraine
Interventions
Drug: Placebo
First Posted Date
2024-09-19
Last Posted Date
2025-07-08
Lead Sponsor
Biohaven Therapeutics Ltd.
Target Recruit Count
647
Registration Number
NCT06603623
Locations
🇺🇸

MD First Research, Gilbert, Arizona, United States

🇺🇸

WR-PRI, LLC (Encino), Encino, California, United States

🇺🇸

Cenexel CNS Los Alamitos, Los Alamitos, California, United States

and more 56 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.